Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences’ Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants
August 30 2021 - 7:00AM
(NASDAQ: ENOB) – Enochian BioSciences, a company focused on
gene-modified cellular and immune therapies for infectious diseases
and cancer, announced the appointment of internationally renowned
scientists and public health leaders to a Scientific Advisory Board
(SAB) focused on potential inhaled treatment and prevention of any
current or future variants of SARS-CoV-2 – the virus that causes
COVID-19 – and Influenza.
- Dr. Peter Piot, KCMG, FRCP, FMedSci,
Chairperson of the SAB, is the Handa Professor of Global
Health, London School of Hygiene and Tropical Medicine, former
founding Director of UNAIDS and co-discoverer of the Ebola virus.
He is also a member of the US National Academy of Medicine.
- Dr. Richard Whitley, MD, Distinguished
Professor, University of Alabama Birmingham, is a leading basic and
clinical researcher who has published more than 380 scientific
articles.
“I have been working on pandemics for over 40 years, and was
blown away by the brilliant creativity of the inventor, Dr. Serhat
Gumrukçu, and the sophistication and elegance of the scientific
approach to potentially treat and prevent any variants of
SARS-CoV-2 and Influenza,” said Dr. Piot. “If the impressive
results in animal models are confirmed in people, there is the
potential to contribute significantly to fighting COVID-19. Perhaps
as important, it is possible that Enochian’s products could prevent
future pandemic threats from corona- and influenza viruses.”
“I am excited to be involved with Enochian BioSciences as they
try to move quickly to advance products that could potentially be
important to control and, ultimately end, the COVID-19 pandemic,”
Dr. Whitley said. “The Delta variant reproduces so quickly that
even vaccinated people with no symptoms can have as much virus in
their airways as unvaccinated people, contributing to rapid spread.
Enochian’s unique and innovative approach to kill cells infected
with the virus in the nose, mouth and lungs could potentially both
limit illness but also spread for a win-win.”
Dr. Mark Dybul, Enochian’s CEO said, “We are thrilled that some
of the top experts in the world seem as excited as we are about the
potential for our products to play a key role in combating
COVID-19, but also the potential for them to help prevent two of
the greatest pandemic threats for the future – Influenza and
another Coronavirus. The experience and knowledge the SAB brings
will help accelerate Enochian’s efforts to advance the research
and, we hope, ultimately to save lives.”
About Enochian BioSciences, Inc. Enochian
BioSciences, Inc. is a biopharmaceutical company focused on
developing innovative platforms for gene-modified cellular and
immune therapies to potentially cure and treat deadly diseases. The
company’s gene-modified cell and immune therapy platforms can
potentially be applied to multiple indications, including HIV/AIDS,
Hepatitis B, all Corona and Influenza viruses, and Oncology. For
more information, please visit Enochianbio.com
Forward-Looking Statements Statements in this
press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties, including but not limited to the
success or efficacy of our pipeline. All statements other than
historical facts are forward-looking statements, which can be
identified by the use of forward-looking terminology such as
“believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or
similar expressions. Actual events or results may differ materially
from those projected in any of such statements due to various
uncertainties, including as set forth in Enochian BioSciences’ most
recent Annual Report on Form 10-K filed with the SEC. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and Enochian BioSciences undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof.
Contact: ir@enochianbio.com
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Apr 2023 to Apr 2024